Kohei Shitara: Pleased To Report FGFR2b Expression In Gastric Cancer and Relationship With Other Biomarkers Published in ESMO Open

Kohei Shitara, Medical Oncologist at National Cancer Center Hospital East, Japan, shared a post on X:

“Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers in ESMO Open.

The results of bemarituzumab phase 3 studies are awaited.”

FGFR2b

Title: Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma

Journal: ESMO Open

Authors: S. Sato, S.L. Rhodes, Y. Aoki, I. Nakayama, T. Hashimoto, J. Hawkins, R.E. Yanes, C.-H. Chang, Y. Nakamura, A. Kawazoe, S. Mishima, D. Kotani, Y. Kuboki, H. Bando, T. Kojima, S. Yoshino, S. Reading, H. Honeycutt, E. Finger, I. Endo, N. Sakamoto, T. Kuwata, T. Yoshino, K. Shitara

Read the full article.

FGFR2b

More posts featuring Kohei Shitara on OncoDaily.

Insight

A. Kawazoe C.-H. Chang cancer D. Kotani E. Finger ESMO Open FGFR2b gastric cancer H. Bando H. Honeycutt I. Endo I. Nakayama J. Hawkins K. Shitara Kohei shitara N. Sakamoto OncoDaily Oncology R.E. Yanes S. Mishima S. Reading S. Sato S. Yoshino S.L. Rhodes T. Hashimoto T. Kojima T. Kuwata T. Yoshino Y. Aoki Y. Kuboki Y. Nakamura